Novavax and Moderna Shares Fall as Plague Fears Subside and Citi Issues Commentary

Key Facts

1Shares of Novavax and Moderna declined following a decrease in concerns regarding a plague outbreak.

2Comments from Citigroup contributed to the downward pressure on vaccine manufacturers' stock performance.

Shares of Novavax and Moderna declined following a decrease in concerns regarding a potential plague outbreak. Investing.com reported that comments from Citigroup contributed to downward pressure on vaccine manufacturers, reversing recent speculative gains driven by health sector volatility.

NVAX closed at $11.32 on October 6, 2026, after experiencing a trading range between a high of $13.33 and a low of $10.88 during the same session. The decline reflects a broader shift in market sentiment as perceived health threats subside and analysts issue more cautious outlooks for the industry.